Corcept Therapeutics (CORT) Return on Capital Employed (2011 - 2026)

Corcept Therapeutics (CORT) has 16 years of Return on Capital Employed data on file, last reported at 1.21% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed fell 1704.0% year-over-year to 1.21%; the trailing twelve-month figure through Mar 2026 stood at 1.21% (down 1704.0% YoY), and the FY2025 full-year result was 6.66%, down 1654.0% from the prior year.
• Return on Capital Employed fell to 1.21% in Q1 2026, from 6.75% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 33.86% in Q1 2022 to a low of 1.21% in Q1 2026.
• A 5-year average of 19.58% and a median of 21.32% in 2023 frame the typical range for Return on Capital Employed.
• Across the five-year window, Return on Capital Employed soared 1274 bps in 2022 and sank 1704 bps in 2026, its largest moves.
• Tracing CORT's Return on Capital Employed over 5 years: stood at 23.18% in 2022, then retreated by 8 bps to 21.32% in 2023, then retreated by 4 bps to 20.39% in 2024, then tumbled by 67 bps to 6.75% in 2025, then slumped by 118 bps to 1.21% in 2026.
• Business Quant data shows CORT's Return on Capital Employed at 1.21% in Q1 2026, 6.75% in Q4 2025, and 10.24% in Q3 2025.